Erythrasma treated with single-dose clarithromycin

Archives of Dermatology

Volumn 134, Issue 6, 1998, Pages 671-672

  Wharton, James R ^a   Wilson, Patricia L ^a   Kincannon, Jay M ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLARITHROMYCIN;

BACTERIAL INFECTION; CASE REPORT; CORYNEBACTERIUM; COST EFFECTIVENESS ANALYSIS; DOSE RESPONSE; DRUG SAFETY; DRUG TOLERANCE; HUMAN; ORAL DRUG ADMINISTRATION; PATIENT COMPLIANCE; PRIORITY JOURNAL; SHORT SURVEY;

ANTI-BACTERIAL AGENTS; CLARITHROMYCIN; CORYNEBACTERIUM; ERYTHRASMA; HUMANS; PROTEIN SYNTHESIS INHIBITORS;

EID: 0031780744     PISSN: 0003987X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archderm.134.6.671     Document Type: Short Survey

References (5)

1. Hodson SB, Henslee TM. Interdigital erythrasma, part I: a review of the literature. J Am Podiatr Med Assoc. 1988:78:551-558.
2. Sindhuphak W, MacDonald E, Smith EB. Erythrasma overlooked or misdiagnosed? Int J Dermatol. 1995:24:95-96.
3. Sturgill MG, Rapp RP. Clarithromycin: review of a new macrolide antibiotic with improved microbiologic spectrum and favorable pharmacokinetic and adverse effect profiles. Ann Pharmacother. 1992:26:1088-1099.
4. Zuckerman JM, Kaye KM. The newer macrolides: azithromycin and clarithromycin. Infect Dis Clin North Am. 1995;9:731-745.
5. Fraschini F, Scaglione F, Demartini G. Clarithromycin clinical pharmacokinetics. Clin Pharmacokinet. 1993:25:189-204.